Top

Osteoporosis International

Published in:

01-11-2014 | Original Article

Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury

Authors: C. O. Tan, R. A. Battaglino, A. L. Doherty, R. Gupta, A. A. Lazzari, E. Garshick, R. Zafonte, L. R. Morse

Published in: Osteoporosis International | Issue 11/2014

Abstract

Summary

We explored the association between adiponectin levels and bone strength in paralyzed men with spinal cord injury. We found that bone strength was inversely associated with circulating adiponectin levels. Thus, strength estimates and adiponectin levels may improve fracture risk prediction and detection of response to osteogenic therapies following spinal cord injury.

Purpose

Previous research has demonstrated an inverse relationship between circulating adiponectin and bone mineral density, suggesting that adiponectin may be used as a biomarker for bone health. However, this relationship may reflect indirect effects on bone metabolism via adipose-mediated mechanical pathways rather than the direct effects of adipokines on bone metabolism. Thus, we explored the association between circulating adiponectin levels and bone strength in 27 men with spinal cord injury.

Methods

Plasma adiponectin levels were quantified by ELISA assay. Axial stiffness and maximal load to fracture of the distal femur were quantified via finite element analysis using reconstructed 3D models of volumetric CT scans. We also collected information on timing, location, and cause of previous fractures.

Results

Axial stiffness and maximal load were inversely associated with circulating adiponectin levels (R ² = 0.44, p = 0.01; R ² = 0.58, p = 0.05) after adjusting for injury duration and lower extremity lean mass. In individuals with post-SCI osteoporotic fractures, distal femur stiffness (p = 0.01) and maximal load (p = 0.005) were lower, and adiponectin was higher (p = 0.04) than those with no fracture history.

Conclusions

Based on these findings, strength estimates may improve fracture risk prediction and detection of response to osteogenic therapies following spinal cord injury. Furthermore, our findings suggest that circulating adiponectin may indeed be a feasible biomarker for bone health and osteoporotic fracture risk in paralyzed individuals with spinal cord injury.

Reid IR (2008) Relationships between fat and bone. Osteoporos Int 19:595–606PubMedCrossRef

Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM (2011) Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1–84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab 96:E1982–E1989PubMedCrossRefPubMedCentral

Zhang Y, Zhou P, Kimondo JW (2012) Adiponectin and osteocalcin: relation to insulin sensitivity. Biochem Cell Biol 90:613–620PubMedCrossRef

Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543PubMedCrossRef

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869PubMedCrossRef

Johansson H, Oden A, Lerner UH, Jutberger H, Lorentzon M, Barrett-Connor E, Karlsson MK, Ljunggren O, Smith U, McCloskey E, Kanis JA, Ohlsson C, Mellstrom D (2012) High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res 27:1390–1396PubMedCrossRef

Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849PubMedCrossRef

Yokota T, Meka CS, Medina KL, Igarashi H, Comp PC, Takahashi M, Nishida M, Oritani K, Miyagawa J, Funahashi T, Tomiyama Y, Matsuzawa Y, Kincade PW (2002) Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest 109:1303–1310PubMedCrossRefPubMedCentral

Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY (2005) Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99–109PubMedCrossRef

10.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648–1656PubMedCrossRef

11.

Jurimae J, Jurimae T (2007) Adiponectin is a predictor of bone mineral density in middle-aged premenopausal women. Osteoporos Int 18:1253–1259PubMedCrossRef

12.

Jurimae J, Jurimae T (2007) Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab 293:E42–E47PubMedCrossRef

13.

Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517–1523PubMedCrossRef

14.

Basurto L, Galvan R, Cordova N, Saucedo R, Vargas C, Campos S, Halley E, Avelar F, Zarate A (2009) Adiponectin is associated with low bone mineral density in elderly men. Eur J Endocrinol 160:289–293PubMedCrossRef

15.

Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY (2008) Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387:31–35PubMedCrossRef

16.

Baldock P (2011) Reciprocal regulation of bone and energy metabolism. Horm Res Paediatr 76(Suppl 1):7–11PubMedCrossRef

17.

Doherty AL, Battaglino RA, Donovan J, Gagnon D, Lazzari AA, Garshick E, Zafonte R, Morse LR (2014) Adiponectin is a candidate biomarker of lower extremity bone density in men with chronic spinal cord injury. J Bone Miner Res 29:251–259PubMedCrossRef

18.

Friedman AW (2006) Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol 12:70–77PubMedCrossRef

19.

Tuukkanen J, Koivukangas A, Jamsa T, Sundquist K, Mackay CA, Marks SC Jr (2000) Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J Bone Miner Res 15:1905–1911PubMedCrossRef

20.

Morse LR, Lazzari AA, Battaglino R, Stolzmann KL, Matthess KR, Gagnon DR, Davis SA, Garshick E (2009) Dual energy X-ray absorptiometry of the distal femur may be more reliable than the proximal tibia in spinal cord injury. Arch Phys Med Rehabil 90:827–831PubMedCrossRefPubMedCentral

21.

Shapiro LG, Stockman GC, (2001) Computer Vision. Prentice-Hall, Upper Saddle River

22.

Fang Q, Boas D. (2009) Tetrahedral mesh generation from volumetric binary and gray-scale images. Proc Intern Symp Biomed Imaging 1142–1145

23.

Cody DD, Gross GJ, Hou FJ, Spencer HJ, Goldstein SA, Fyhrie DP (1999) Femoral strength is better predicted by finite element models than QCT and DXA. J Biomech 32:1013–1020PubMedCrossRef

24.

Huiskes R, Chao EY (1983) A survey of finite element analysis in orthopedic biomechanics: the first decade. J Biomech 16:385–409PubMedCrossRef

25.

Keyak JH, Rossi SA, Jones KA, Skinner HB (1998) Prediction of femoral fracture load using automated finite element modeling. J Biomech 31:125–133PubMedCrossRef

26.

Dreiseitl S, Ohno-Machado L, Vinterbo S. (1999) Evaluating variable selection methods for diagnosis of myocardial infarction. Proc AMIA Symp 246–250

27.

Steyerberg EW, Eijkemans MJ, Habbema JD (1999) Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935–942PubMedCrossRef

28.

Agbaht K, Gurlek A, Karakaya J, Bayraktar M (2009) Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density. Endocrine 35:371–379PubMedCrossRef

29.

Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, Kanaya AM, Harris TB, Cauley JA (2012) The effects of adiponectin and leptin on changes in bone mineral density. Osteoporos Int 23:1699–1710PubMedCrossRefPubMedCentral

30.

Huang KC, Cheng WC, Yen RF, Tsai KS, Tai TY, Yang WS (2004) Lack of independent relationship between plasma adiponectin, leptin levels and bone density in nondiabetic female adolescents. Clin Endocrinol (Oxf) 61:204–208CrossRef

31.

Iacobellis G, Iorio M, Napoli N, Cotesta D, Zinnamosca L, Marinelli C, Petramala L, Minisola S, D’Erasmo E, Letizia C (2011) Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J Endocrinol Investig 34:e12–e15CrossRef

32.

Jurimae J, Jurimae T, Leppik A, Kums T (2008) The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab 26:618–623PubMedCrossRef

33.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2009) Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 160:265–273PubMedCrossRef

34.

Bauman WA, Spungen AM, Wang J, Pierson RN Jr, Schwartz E (2006) Relationship of fat mass and serum estradiol with lower extremity bone in persons with chronic spinal cord injury. Am J Physiol Endocrinol Metab 209:E1098–E1103CrossRef

35.

Misra M, Klibanski A (2013) Anorexia nervosa, obesity and bone metabolism. Pediatr Endocrinol Rev 11:21–33PubMedPubMedCentral

36.

Martin RB (1991) Determinants of the mechanical properties of bones. J Biomech 24(Suppl 1):79–88PubMedCrossRef

37.

Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, Kanaya AM, Harris TB, Bauer DC, Cauley JA (2011) Adipokines and the risk of fracture in older adults. J Bone Miner Res 26:1568–1576PubMedCrossRefPubMedCentral

38.

Jurimae J, Kums T, Jurimae T (2009) Adipocytokine and ghrelin levels in relation to bone mineral density in physically active older women: longitudinal associations. Eur J Endocrinol 160:381–385PubMedCrossRef

39.

Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM (2013) The clinical utility of bone marker measurements in osteoporosis. J Transl Med 11:201PubMedCrossRefPubMedCentral

40.

Morse LR, Sudhakar S, Lazzari AA, Tun C, Garshick E, Zafonte R, Battaglino RA (2013) Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int 24:961–968PubMedCrossRefPubMedCentral

41.

Dauty M, Perrouin VB, Maugars Y, Dubois C, Mathe JF (2000) Supralesional and sublesional bone mineral density in spinal cord-injured patients. Bone 27:305–309PubMedCrossRef

42.

Garland DE, Stewart CA, Adkins RH, Hu SS, Rosen C, Liotta FJ, Weinstein DA (1992) Osteoporosis after spinal cord injury. J Orthop Res 10:371–378PubMedCrossRef

43.

Vestergaard P, Krogh K, Rejnmark L, Mosekilde L (1998) Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord 36:790–796PubMedCrossRef

Title: Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury
Authors: C. O. Tan
R. A. Battaglino
A. L. Doherty
R. Gupta
A. A. Lazzari
E. Garshick
R. Zafonte
L. R. Morse
Publication date: 01-11-2014
Publisher: Springer London
Published in: Osteoporosis International / Issue 11/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2786-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury

Abstract

Summary

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2014

Comment on Tadrous et al.: Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis

Reconsideration of the relevance of mild wedge or short vertebral height deformities across a broad age distribution

Reference equations for ultrasound bone densitometry of the radius in Central European children and adolescents

Erratum to: Management of osteoporosis of the oldest old

The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000–2010

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis—reply to Pazianas and Abrahamsen